Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 12/20 | 0.61 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.54 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 2/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | ILK | Q13418 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25028306 | 0.83 | KDM4E (0.43) | APPSULT1A1GFERPDGFRBPDGFRA | |
| SCHEMBL1637787 | 0.81 | MAPT (0.61) | APPCCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL1637646 | 0.81 | APP (0.58) | APPCCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL2139108 | 0.79 | APP (0.71) | APPCCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL3469331 | 0.77 | RAB9A (0.64) | APPILKKDM4EMEN1ALDH1A1 | |
| SCHEMBL15425178 | 0.76 | APP (0.82) | APPSULT1A1MAOBILKKDM4E | |
| SCHEMBL4804599 | 0.76 | APP (0.82) | APPSULT1A1MAOBKDM4EALDH1A1 | |
| SCHEMBL1977616 | 0.76 | APP (1.00) | APPSULT1A1GFERKDM4EMEN1 | |
| SCHEMBL12207347 | 0.76 | APP (1.00) | APPSULT1A1GFERKDM4EMEN1 | |
| SCHEMBL1638045 | 0.76 | CDK5 (0.60) | APPCDK5CDK5R1SULT1A1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098292-A1 | New Compounds Useful for Treating CNS Disorders | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | claimed |
| CN-1980922-A | New compounds useful for treating CNS disorders | ASTRAZENECA AB (SE) | 2007-06-13 | — | — | CN | claimed |
| EP-1765815-A2 | NEW COMPOUNDS USEFUL FOR TREATING CNS DISORDERS | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | claimed |
| WO-2006004507-A2 | NEW BENZOTHIAZOLE DERIVATIVES USEFUL FOR TREATING CNS DISORDERS | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | claimed |
| US-20110098292-A1 | New Compounds Useful for Treating CNS Disorders | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | disclosed |
| CN-1980922-A | New compounds useful for treating CNS disorders | ASTRAZENECA AB (SE) | 2007-06-13 | — | — | CN | disclosed |
| EP-1765815-A2 | NEW COMPOUNDS USEFUL FOR TREATING CNS DISORDERS | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006004507-A2 | NEW BENZOTHIAZOLE DERIVATIVES USEFUL FOR TREATING CNS DISORDERS | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098292-A1 | New Compounds Useful for Treating CNS Disorders | SLC18A2, PMP22, GAP43 | APP 543/4885CCNE1 4159/4885CDK2 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.